Loading…
← CockpitCompetitor Analysis › ENTX Entera Bio Ltd.Open in the cockpit ↗

Entera Bio Ltd.ENTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum leader 98
Mkt cap
$568M
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$769,965
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 12.5%
Hurdle
n/a
no reverse DCF
Next earnings
128 days
26 Mar 2027
Close · USD$3.26
1D+8.7%
1W+1.2%
1M+8.0%
3M+1.2%
6M+162.9%
YTD+68.0%
1Y+21.6%
ATR %6.0%
Beta0.88
52w lowhigh22.4% off high

What Entera Bio does

Employees: 22

Entera Bio at a glance

Size Entera Bio (ENTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $568M, the 2581st largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.26 on 18 Nov 2026.

Performance Over six months the shares gained 162.9%, against -21.2% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue fell 100.0% over the last twelve months (peer median +4.6%).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026ENTX 257Peer median 77
Six months, rebased to 100: Entera Bio against the median of its 20 peers (local-currency closes).

Entera Bio financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$42,000$181,000$0$134,000
Revenue growth—-77%—-100%—
Gross profit-$32,000-$30,000$9,000-$56,000-$31,000
EBITDA-$18.4M-$11.5M-$9.54M-$8.88M-$13.0M
Net income-$29.4M-$11.4M-$9.54M-$8.89M-$13.1M
Free cash flow-$16.1M-$7.48M-$6.82M-$7.33M-$12.5M
Capital expenditure$53,921$107,000$3,000$17,000$47,000
Total debt$397,000$490,000$272,000$390,000$91,000

Quarterly statements and history in the cockpit →

Entera Bio competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%ALMS68835660056836132256002393474321570038506034394559CGEM002688300147MOREPENLABIMMXSENORESENTX6-month return →1-month return →
Up and to the right = strong over both horizons. Entera Bio is the large dot.

Entera Bio competitors and peer comparison

How Entera Bio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Entera Bio against its 20 peers (data as of 18 Nov 2026)
MeasureENTXPeer medianRank in peer set
1-month return+8.0%-11.4%2nd highest of 21
6-month return+162.9%-21.2%highest of 21
Distance from 52-week high-22.4%-42.9%3rd highest of 21
Revenue growth (TTM)-100.0%+4.6%lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%23.9×n/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%8.7×36.4%+11.2%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%6.2×n/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%1.9×-15.4%+2.8%
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%20.1×n/an/a
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%1.2×-5.8%+4.1%
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%101.5×n/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%4.5×n/an/a
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%69.1×n/an/a
Boryung 003850.KSSouth Korea$554M-13%+6%6%0.9×-3.1%+12.6%
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%2.6×20.9%+21.9%
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%2.4×-4.9%+51.6%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%1.0×-12.3%+11.1%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%1.8×1.0%+9.7%
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%2.2×n/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%7.4×n/an/a

Questions

Which companies are Entera Bio's closest peers?
The cockpit's peer set: Alumis (ALMS), Jenkem Technology (688356.SS), Zhong Zhu Healthcare (600568.SS), Beijing Tong Ren Tang Chinese Medicine (3613.HK), Abbisko Cayman (2256.HK), Tianjin Lisheng Pharmaceutical (002393.SZ), Oneness Biotech (4743.TWO), Lepu Biopharma (2157.HK).
How has Entera Bio stock performed?
Over six months to 18 Nov 2026 the shares returned +162.9% against -21.2% for the median peer; over one year +21.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.